Marissa A Zarakas1, Jigar V Desai1, Georgios Chamilos2, Michail S Lionakis1. 1. Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 2. Department of Clinical Microbiology and Microbial Pathogenesis, School of Medicine, University of Crete, Greece, and Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, 71300, Heraklion, Crete, Greece.
Abstract
PURPOSE OF REVIEW: Small molecule kinase inhibitors (SMKIs) have revolutionized the management of malignant and autoimmune disorders. Emerging clinical reports point toward an increased risk for invasive fungal infections (IFIs) in patients treated with certain SMKIs. In this mini-review, we highlight representative examples of SMKIs that have been associated with or are expected to give rise to IFIs. RECENT FINDINGS: The clinical use of the Bruton's tyrosine kinase inhibitor ibrutinib as well as other FDA-approved SMKIs has been associated with IFIs. The fungal infection susceptibility associated with the clinical use of certain SMKIs underscores their detrimental effects on innate and adaptive antifungal immune responses. SUMMARY: The unprecedented development and clinical use of SMKIs is expected to give rise to an expansion of iatrogenic immunosuppressive factors predisposing to IFIs (and other opportunistic infections). Beyond increased clinical surveillance, better understanding of the pathogenesis of SMKI-associated immune dysregulation should help devising improved risk stratification and prophylaxis strategies in vulnerable patients.
PURPOSE OF REVIEW: Small molecule kinase inhibitors (SMKIs) have revolutionized the management of malignant and autoimmune disorders. Emerging clinical reports point toward an increased risk for invasive fungal infections (IFIs) in patients treated with certain SMKIs. In this mini-review, we highlight representative examples of SMKIs that have been associated with or are expected to give rise to IFIs. RECENT FINDINGS: The clinical use of the Bruton's tyrosine kinase inhibitor ibrutinib as well as other FDA-approved SMKIs has been associated with IFIs. The fungal infection susceptibility associated with the clinical use of certain SMKIs underscores their detrimental effects on innate and adaptive antifungal immune responses. SUMMARY: The unprecedented development and clinical use of SMKIs is expected to give rise to an expansion of iatrogenic immunosuppressive factors predisposing to IFIs (and other opportunistic infections). Beyond increased clinical surveillance, better understanding of the pathogenesis of SMKI-associated immune dysregulation should help devising improved risk stratification and prophylaxis strategies in vulnerable patients.
Authors: Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter Journal: Cancer Res Date: 2006-12-15 Impact factor: 12.701
Authors: Scott Wilhelm; Christopher Carter; Mark Lynch; Timothy Lowinger; Jacques Dumas; Roger A Smith; Brian Schwartz; Ronit Simantov; Susan Kelley Journal: Nat Rev Drug Discov Date: 2006-10 Impact factor: 84.694
Authors: Madeleine M Hipp; Norbert Hilf; Steffen Walter; Daniela Werth; Katharina M Brauer; Markus P Radsak; Toni Weinschenk; Harpreet Singh-Jasuja; Peter Brossart Journal: Blood Date: 2008-02-29 Impact factor: 22.113
Authors: Salomé LeibundGut-Landmann; Olaf Gross; Matthew J Robinson; Fabiola Osorio; Emma C Slack; S Vicky Tsoni; Edina Schweighoffer; Victor Tybulewicz; Gordon D Brown; Jürgen Ruland; Caetano Reis e Sousa Journal: Nat Immunol Date: 2007-04-22 Impact factor: 25.606
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Jeremy A W Gold; Seda S Tolu; Tom Chiller; Kaitlin Benedict; Brendan R Jackson Journal: Clin Infect Dis Date: 2022-08-25 Impact factor: 20.999
Authors: Adam L Viens; Kyle D Timmer; Natalie J Alexander; Rana Barghout; Jelena Milosevic; Alex Hopke; Natalie J Atallah; Allison K Scherer; David B Sykes; Daniel Irimia; Michael K Mansour Journal: J Immunol Date: 2022-03-11 Impact factor: 5.422